

## Fentanyl Plus<sup>+</sup> Drug Screen

Revised 10-24-2023

<b>Test Description</b>	Quantitative screening assay for the presumptive identification of opiates, opioids, prescription drugs, illicit drugs, and their metabolites in urine, including novel drug analogues and associated Tentatively Identified Compounds (TICs).
<b>Test Use</b>	To aid in the surveillance of illicit drug use in hospital emergency department admissions due to overdose.
<b>Test Department</b>	CT DPH Laboratory - Clinical Chemistry Phone: (860) 920-6592 Fax: (860) 920-6718
<b>Methodology</b>	Liquid Chromatography/Tandem Mass Spectrometry: LC MS/MS QTOF X500R
<b>Availability</b>	Daily, Monday-Friday
<b>Specimen Requirements</b>	Urine, 2.0-10.0 mL Low specimen volume may compromise repeat analysis or confirmatory testing.
<b>Collection Kit/Container</b>	Single-use plastic urine collection container, leak resistant. Containers and urine tube aliquots that contain additives/stabilizers cannot be tested.
<b>Collection Instructions</b>	Collect urine midstream (clean catch), by catheterization, or suprapubic aspiration. A sterile specimen is not required.
<b>Specimen Handling &amp; Transport</b>	Store specimens at 2-8° C for up to 24 hours. If a delay is expected, store specimens at -20° C or lower. Transport specimens using ice packs.
<b>Unacceptable Conditions</b>	Unlabeled specimen. Insufficient specimen volume. Specimens that have leaked or containers that have broken in transit. Specimens not collected or handled as described above.
<b>Requisition Form</b>	Clinical Test Requisition OL-9B, under Test Not Listed (Specify), write in "Fentanyl Plus <sup>+</sup> Drug Screen".
<b>Required Information</b>	Name and address of submitter. Two patient identifiers (ie. name, DOB, Acc.#, MRN), name of provider, specimen type or source, date of collection, test requested. Please ensure patient information on the requisition matches that on the specimen.
<b>Limitations</b>	Screening is limited <b>only</b> to clinical specimens from patients that present at hospital emergency departments and meet the defined criteria for overdose.
<b>Additional Comments</b>	Screening is offered for surveillance purposes only under the CT DPH Injury Prevention Program and is not valid for medicolegal use. Screening alone may not identify novel compounds, with independent confirmation indicated.